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OBJECTIVE — Thereisahighprevalenceofhypogonadisminmenwithtype2diabetes.This
will lead to an increase in assessments of hypogonadism. Statins could potentially decrease
testosterone levels by reducing the availability of cholesterol for androgen synthesis. We com-
paredtestosteronelevelsandhypogonadalsymptomswithstatinuseinacross-sectionalstudyof
355 men with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Total testosterone, sex hormone–binding
globulin (SHBG), and estradiol were measured by an enzyme-linked immunosorbent assay.
Bioavailable testosterone was measured by the modiﬁed ammonium sulfate precipitation
method. Free testosterone was calculated using Vermeulen’s formula. Symptoms of hypogonad-
ism were assessed using the Androgen Deﬁciency in the Aging Male questionnaire.
RESULTS — Statins were associated with lower total testosterone (11.9 vs. 13.4 nmol/l, P 
0.006) and a trend toward lower SHBG (29.4 vs. 35.3 nmol/l, P  0.034) compared with no
treatment. Bioavailable testosterone, free testosterone, estradiol, and hypogonadal symptoms
were not affected. Subanalysis showed that atorvastatin was associated with reduced total tes-
tosterone (11.4 vs. 13.4 nmol/l, P  0.006) and a trend toward reduced SHBG (27.6 vs. 35.3
nmol/l,P0.022)comparedwithnotreatment,andtherewasanapparentdose-responseeffect
with the lowest levels of total testosterone seen in men treated with 20 mg atorvastatin (9.6
nmol/l, P  0.017). Simvastatin use was not associated with signiﬁcant reductions in testoster-
one or SHBG levels.
CONCLUSIONS — Assessing androgen status using total testosterone in men with type 2
diabetes treated with statins, particularly atorvastatin, may potentially lead to diagnostic error.
Levels of bioavailable testosterone or free testosterone are recommended for the assessment of
hypogonadism in this group if total testosterone levels are borderline.
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T
here is evidence that men with the
metabolic syndrome, type 2 diabe-
tes, and cardiovascular disease have
a high prevalence of low circulating levels
of testosterone (1). A signiﬁcant propor-
tion of these men are hypogonadal, de-
ﬁned as a combination of clinical
symptoms and biochemical evidence of
testosterone deﬁciency (2). The lower
limit of normal serum testosterone levels,
which deﬁnes the biochemical diagnosis
of hypogonadism, is not fully clear. Stud-
ies have shown that about 20% of men
with metabolic syndrome, diabetes, and
cardiovascular disease have testosterone
levelsbelowthenormalrange,andthereare
a further 20–25% with levels in the low
normal range that may also be compatible
withadiagnosisofhypogonadism,depend-
ing on clinical symptoms (1,2).
Thegreatmajorityofmenwithdiabe-
tes and cardiovascular disease are being
treated with statins. Cholesterol is the
substrate for testosterone biosynthesis,
and theoretically, hydroxymethylglu-
taryl-CoA reductase inhibitors such as st-
atins could affect serum testosterone
levels. Animal studies have shown that st-
atins can reduce testosterone production
when given in high doses (3). Studies in
humans, mostly involving small numbers
of men, have shown various results. The
majority have shown no effect of statins
on testosterone levels (4–8), but some
have shown reduced testosterone levels
with simvastatin treatment (9–11).
Total testosterone is the most widely
used biochemical test in the diagnosis of
men with hypogonadism. Total testoster-
one comprises free testosterone (2–3%)
and testosterone bound to either sex hor-
mone–binding globulin (SHBG) (60–
80%) or albumin (20–40%) (12). Free
plus albumin-bound testosterone is gen-
erally regarded as the biologically active
or bioavailable component. Testosterone
bound to SHBG is considered to be inac-
tive although recent research has sug-
gested that SHBG-bound testosterone
may be taken into cells by endocytosis,
possibly allowing biological actions (13).
Studies have demonstrated that bioavail-
able or free testosterone better reﬂects
androgen status, for example, by correla-
tions with bone mineral density (14) and
erectile dysfunction (15). Laboratory
measures of bioavailable and free testos-
terone are not routinely available, as they
are time-consuming and only small num-
bers of tests can be analyzed simulta-
neously. Mathematical formulae to
calculate these fractions based on total
testosterone and SHBG are available but
have to be validated locally before clinical
use because of differences in total testos-
terone assays (16,17).
We have here analyzed the effect of
statins on testosterone levels in a cross-
sectional epidemiological study of men
withtype2diabetes.Theinitialstudywas
the ﬁrst to investigate the prevalence of
hypogonadism in men with diabetes
rather than only assessing testosterone
levels (2). It showed that 14% of the men
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abletestosterone,17%hadtotaltestoster-
one levels 8 nmol/l (231 ng/dl), and
42% had total testosterone levels 12
nmol/l (346 ng/dl); these are arbitrary
cutoffs for levels compatible with hypo-
gonadismtakenfrominternationalguide-
lines (18). We have reexamined the effect
of the statins on all testosterone parame-
tersandclinicalhypogonadisminthisco-
hort compared with those men not taking
statins. The clinical data were collated in
years 2002–2003 when only approxi-
mately half of the men in the study were
treated with statins.
RESEARCH DESIGN AND
METHODS— Men, aged 30 years,
with type 2 diabetes were recruited from
Barnsley Hospital NHS Trust, Barnsley,
U.K., in years 2002–2003. Subjects were
approached during outpatient appoint-
ments at the Centre for Diabetes and En-
docrinology. Most of the subjects were
recruited from the retinal screening pro-
gram, which is attended by virtually all
patients with diabetes in the Barnsley
area. Subjects were given written and ver-
bal information regarding the study, and
355 men gave their informed consent to
take part. The study population com-
prised patients with diabetes usually
managed in primary care facilities as well
as secondary care patients. All partici-
pants were of Caucasian origin.
Demography, medical history, and
drug histories were collected using a
questionnaire. Clinical and biochemical
assessments of androgen status were
made. Other measurements included
bloodpressure,A1C,nonfastinglipidlev-
els, height, weight, and waist circumfer-
ence. The main data from the study were
publishedpreviouslyinDiabetesCare(2).
This is a subanalysis of data relating to
statin use.
Assessments
Patients were seen in the morning be-
tween 8:00 and 10:00 A.M. Symptoms of
hypogonadism were assessed by comple-
tion of the Androgen Deﬁciency in the
Aging Male (ADAM) questionnaire,
whichwasvalidatedtoassesshypogonad-
ism in aging men (19). Venous blood was
taken, and serum samples were produced
bycentrifugation.Patientsdidnotfastbe-
fore having samples taken. Serum sam-
ples were then stored at 20°C for future
analysis. Serum total testosterone, total
estradiol,andSHBGweremeasuredbyan
enzyme-linked immunosorbent assay
using commercially available kits (DRG
Diagnostics, Marburg, Germany). Bio-
available testosterone was determined by
a modiﬁcation of the ammonium sulfate
precipitation method described by Trem-
blayandDube(20).Freetestosteronewas
calculated from total testosterone and
SHBG by the formula of Vermeulen et al.
(16).Thesemethodsofassessingbioavail-
able and free testosterone have been used
in previous studies from our research
team and have determined to be reliable
for the assessment of men with diabetes
and vascular disease (17).
Weightandheightwererecordedand
used to derive BMI. Waist circumference
was measured midway between the lower
costal margins and the iliac crests. Blood
pressure was recorded using a manual
sphygmomanometer. A1C was assessed
using a Menarini Analyser HA8160
(Menarini Diagnostics, Florence, Italy).
Serum lipid parameters were assessed by
Olympus analyzers (Olympus Diagnos-
tics, Hamburg, Germany).
Statistical analysis
Data were analyzed using the SPSS pack-
age (SPSS, Chicago, IL). Testosterone and
SHBG were log-normally distributed and
were converted to a normal distribution
toallowuseofStudent’sttestforcompar-
ison of group means. With smaller
groups, the normal distribution was
assessed using single-sample Kolmog-
orov-Smirnov testing. The two-sample
Kolmogorov-Smirnov test was used to
compare groups when data did not fulﬁll
the normal distribution. Results were ini-
tially considered statistically signiﬁcant
at P  0.05. Because of multiple statis-
tical testing, we performed a Bonferroni
correction to minimize the chance of
type 2 errors. This resulted in statistical
signiﬁcance being deﬁned as P 
0.0102.
RESULTS
Statin use
Inourcross-sectionof355menwithtype
2 diabetes, 186 were not treated with st-
atins. Of 169 men treated with statins, 81
were treated with atorvastatin, 66 with
simvastatin, 15 with pravastatin, and 7
with other statins (3 with ﬂuvastatin, 1
with cerivastatin, and 3 with “unknown
statin”). Doses were not known for some
patients.
Comparison of statin-treated men
with untreated men
Patients treated with statins did not sig-
niﬁcantly differ from untreated individu-
alsinage,waistcircumference,BMI,A1C,
or blood pressure (Table 1). Total choles-
terol and LDL cholesterol levels were
lower in men taking statins, but there
were no signiﬁcant differences in HDL
Table 1—Mean sex hormone levels, measures of obesity, and cholesterol levels in men treated with any statin, atorvastatin, and simvastatin
compared with untreated men
No statin Statin P value Atorvastatin P value Simvastatin P value
Total testosterone (nmol/l) 13.4 11.9 0.006 11.4 0.006 12.47 0.13
Bioavailable testosterone (nmol/l) 4.14 3.90 0.133 3.82 0.151 3.96 0.292
Free testosterone (nmol/l) 0.284 0.263 0.228 0.259 0.308 0.266 0.125
SHBG (nmol/l) 35.3 29.4 0.034 27.6 0.022 31.8 0.392
Estradiol (pmol/l) 23.2 24.0 0.763 24.7 0.193 24.0 0.705
Waist circumference (cm) 109.6 109.8 0.919 111.9 0.26 108.3 0.513
BMI (kg/m
2) 32.19 32.47 0.646 33.52 0.108 31.25 0.252
Total cholesterol (mmol/l) 5.04 4.58 <0.001 4.64 0.001 4.50 <0.001
ADAM score 4.15 4.26 0.26 4.08 0.809 4.3 0.675
P values given for Student’s t test comparing treated patients with the untreated group. Signiﬁcant results (P  0.01) are shown in boldface. Total testosterone was
signiﬁcantly lower in the statin and atorvastatin groups but not in the simvastatin group. Bioavailable and free testosterone levels were not signiﬁcantly lower in any
group. Both statins were associated with lower cholesterol levels, but none of the groups were signiﬁcantly different in terms of obesity.
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shown).
Total testosterone levels were signiﬁ-
cantly lower in men treated with statins,
andtherewasatrendtowardlowerSHBG
levels,butthisdidnotreachstatisticalsig-
niﬁcance(Table1).Bioavailabletestoster-
one, calculated free testosterone, and
serum estrogen levels were not signiﬁ-
cantly different between the groups. The
symptomscorefromtheADAMquestion-
nairewasnotsigniﬁcantlyalteredinthose
men receiving statin therapy.
Comparison of simvastatin- or
atorvastatin-treated men with
untreated men
There were sufﬁcient numbers of men
treated with simvastatin and atorvastatin
to consider these groups more closely
(Tables 1 and 2). These groups were not
signiﬁcantlydifferentfromuntreatedmen
in terms of BMI, waist circumference,
bloodpressure,A1C,orage.Totalcholes-
terol and LDL cholesterol levels were
lower in both groups compared with
those in untreated men but were not sig-
niﬁcantly different between simvastatin-
and atorvastatin-treated groups. Men
treated with simvastatin did not have sig-
niﬁcantly different total, bioavailable, or
free testosterone, estradiol, or SHBG lev-
els than untreated men (Fig. 1 and Table
1). In contrast, men treated with atorva-
statin had an average total testosterone
level 1.96 nmol/l (56 ng/dl) less than that
in untreated men. There was a trend to-
ward lower SHBG levels in this group
(35.3 vs. 27.6 nmol/l, P  0.022). Estra-
diolandfreeandbioavailabletestosterone
were not signiﬁcantly affected. Further
analysis revealed an apparent dose-
responserelationship,withthelowesttes-
tosteronelevelsseeninmentakinghigher
doses of atorvastatin (Table 3). The aver-
age total testosterone level of men taking
20 mg atorvastatin was 3.78 nmol/l
(108 ng/dl) less than that of untreated
men (Table 3), but this value did not
reach statistical signiﬁcance (P  0.017).
SHBG was also reduced without reaching
signiﬁcance(P0.043),butfreeandbio-
available testosterone levels were unal-
tered. No signiﬁcant differences were
seen in sex hormone levels when the sim-
vastatin-treated men were split into simi-
lar groups (data not shown). There were
no signiﬁcant differences in age, BMI,
waist circumference, blood pressure, or
A1C in any of the atorvastatin- or simvas-
tatin-treated subgroups.
CONCLUSIONS— This is the ﬁrst
study to analyze fully testosterone levels
and hypogonadal symptoms in compari-
sonwithstatinuseinapopulationreceiv-
ing routine medical management. Those
treated with atorvastatin had lower levels
of total testosterone with a trend toward
lower SHBG compared with untreated
men, whereas those treated with simva-
statin were not signiﬁcantly affected. The
effects were particularly evident in those
men taking higher doses of atorvastatin.
Statin treatment did not signiﬁcantly af-
fectthebiologicallyactivefractionsoftes-
tosterone, symptoms of hypogonadism,
or estradiol levels.
This study demonstrates that treat-
ment with statins in this group can be a
confounding factor in the assessment of
hypogonadism. Total testosterone is the
primary test used in the diagnosis of hy-
pogonadism,andtheeffectofatorvastatin
could potentially lead to misdiagnosis of
the condition in men with normal free
and bioavailable testosterone levels. Al-
ternatively, it is possible that reductions
in total testosterone without changes in
bioactive testosterone fractions have clin-
ical effects in view of ﬁndings suggesting
thatSHBG-boundtestosteronemaybebi-
ologically active (13). The ADAM ques-
tionnaire failed to detect an increase in
hypogonadal symptoms in groups with
lower total testosterone levels, but the
questionnaire does not correlate closely
withtestosteronelevels,andmenwithdi-
abetes have a high level of false-positive
hypogonadal symptoms (2) such as erec-
tile dysfunction owing to vascular and
neuropathic factors, medications, and
depression.
The ﬁndings suggest that atorvastatin
hassigniﬁcantbiologicaleffectsontestos-
terone. Atorvastatin is a more potent sta-
tin than simvastatin, thus causing a
greater reduction in the total cholesterol
andhencetotaltestosteronelevels.Nopa-
tientsinourstudyweretreatedwithother
potent statins such as rosuvastatin so we
are unable to conﬁrm that atorvastatin re-
duces testosterone and SHBG levels sec-
ondary to more potent effects on
cholesterollevels.Indeed,cholesteroland
other lipid fraction levels were not signif-
icantlydifferentbetweensimvastatin-and
atorvastatin-treated groups.
In a normal physiological state, lu-
teinizing hormone (LH) promotes uptake
of cholesterol by the testis and stimulates
testosterone synthesis. A reduction in tes-
tosterone is sensed by the hypothalamic-
pituitary axis and leads to greater LH
release, which completes a negative feed-
back loop and maintains testosterone
levels. The apparent failure of the hypo-
thalamic-pituitary-testicular axis to re-
spond and maintain testosterone levels in
the statin-treated patients in our study
may be explained by the hypogonadal-
obesity-adipocytokine hypothesis (1).
The majority of the patients in our study
were overweight or obese. In this popula-
tion, greater production of adipocyto-
kines such as tumor necrosis factor-,
interleukin-6, and leptin and increased
estradiol from metabolism of testosterone
by aromatase in adipose tissue inhibit LH
release from the pituitary gland, which
leads to lower circulating testosterone
levels. In our study, gonadotrophin lev-
els were only tested in men with total
testosterone levels 12 mmol/l (2),
leavingusunabletotestthishypothesis.
The most likely reason that bioavailable
Table 2—Characteristics of patients untreated with statins and those treated with atorvasta-
tin and simvastatin
No statin Atorvastatin P value Simvastatin P value
n 169 81 66
Age (years) 58.3 57.9 0.75 60.7 0.1
Waist circumference (cm) 109.6 111.9 0.26 108.3 0.51
BMI (kg/m
2) 32.2 33.5 0.11 31.3 0.25
A1C (%) 7.2 7.2 0.82 7.14 0.6
Systolic blood pressure (mmHg) 145.1 140.7 0.09 142.3 0.33
Diastolic blood pressure (mmHg) 82.8 81.36 0.33 81.4 0.38
Total cholesterol (mmol/l) 5.04 4.64 0.001 4.5 <0.001
HDL cholesterol (mmol/l) 1.16 1.08 0.03 1.16 0.93
LDL cholesterol (mmol/l) 2.9 2.34 <0.001 2.27 <0.001
Triglycerides (mmol/l) 2.44 2.84 0.19 2.54 0.78
P values given for Student’s t test. Signiﬁcant results (P  0.01) are shown in boldface. There were no
signiﬁcant differences in age, anthropomorphic data, glycemic control, or blood pressure. Total and LDL
cholesterol are lower in the statin-treated group, reﬂecting the primary action of the drugs.
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tered despite lower total testosterone is
a homeostatic mechanism via reduced
SHBG production.
An alternative hypothesis is that ator-
vastatin causes a primary reduction in
SHBG with consequent reductions in to-
tal testosterone. There was a consistent
trend toward low SHBG levels in all
groups with reduced levels of total testos-
terone, although these low levels did not
reachstatisticalsigniﬁcance.SHBGispro-
duced in the liver, the primary site of ac-
tion of the statins, but the mechanism by
which statins could alter SHBG is un-
known. SHBG levels are known to be
modulated by a number of factors includ-
ing downregulation by insulin resistance
andupregulationbyestrogens(21).Insu-
lin resistance was not measured, but gly-
cemic control was similar in all groups.
Estrogen levels did not vary among
groups.
We are aware of one clinical trial as-
sessing the effects of atorvastatin on tes-
tosterone levels in men. It was small and
of 3 months’ duration. The results
showed a nonsigniﬁcant fall in total tes-
tosterone and no change in SHBG (4).
These data are insufﬁcient to conﬁrm or
refute our ﬁndings relating to atorvasta-
tin, and it may be that the study allowed
insufﬁcient time for changes to develop.
There are more published data concern-
ing the effects of simvastatin on testoster-
one. Some trials have shown that
simvastatin reduces serum testosterone
levels(9–11),whereasothershaveshown
noeffect(6–8).Ourdatasuggestthatany
effect of simvastatin in reducing serum
testosterone levels is not clinically signif-
icant in men with type 2 diabetes. We are
not aware of any previous evidence for an
effect of any statin on SHBG levels.
International guidelines have sug-
gested that symptomatic men with total
testosterone levels 8 nmol/l (231 ng/dl)
are hypogonadal, that men with total tes-
Figure1—Meantestosteronelevelsinuntreatedmenandthosetreatedwithatorvastatinorsimvastatin;95%CIsareshown.Internationalguidelines
suggest that testosterone replacement is invariably warranted when the total testosterone level is8 nmol/l (231 ng/dl) or the free testosterone level
is 0.18 nmol/l. Treatment may also beneﬁt men with a total testosterone level between 8 and 12 nmol/l (346 ng/dl) or a free testosterone between
0.18 and 0.25 nmol/l. *P  0.01; P  0.05.
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donothavehypogonadism,andthatmen
with levels between 8 and 12 nmol/l need
considerationfortreatmentdependingon
their clinical picture (18). An Endocrine
Society Clinical Practice Guideline sug-
gested a diagnostic cutoff value of testos-
terone of 10.4 nmol/l (300 ng/dl) for
hypogonadism. Our ﬁndings are impor-
tant in this context because statin treat-
ment was associated with lower total
testosteronelevelsof11.9nmol/l(340ng/
dl) (versus 13.4 nmol/l [384 ng/dl]). Men
treatedwith20mg/dayatorvastatinhad
an average total testosterone level of only
9.6 nmol/l (275 ng/dl), which is 3.8
nmol/l(109ng/dl)lowerthanthatofmen
nottreatedwithstatins.Thus,statintreat-
ment may lead to reductions in total tes-
tosterone levels to 12 or 10.4 nmol/l in
many men but will not signiﬁcantly alter
bioavailable or free testosterone levels or
hypogonadal symptoms. We recommend
alowthresholdformeasuringorcalculat-
ing bioavailable or free testosterone in
men receiving statin therapy.
Testosterone levels are frequently re-
ducedinmenwithtype2diabetes(2,22).
It has now been conﬁrmed that reduc-
tions in total testosterone are accompa-
nied by similar changes in free and
bioavailable testosterone and a high prev-
alence of hypogonadal symptoms (2).
Furthermore, short-term studies in small
numbers of hypogonadal diabetic men
have shown improvements in glycemic
control, central obesity, and serum leptin
during testosterone replacement therapy
(23,24). Other short-term studies have
shown beneﬁcial effects on further car-
diovascular risk factors including total
cholesterollevels(25).Inthiscontext,the
assessmentofhypogonadisminmenwith
type 2 diabetes is likely to increase in
frequency. Assessment of the clinical
syndrome of hypogonadism can be chal-
lenging in this group because of the con-
founding effects of vascular disease,
psychologicalfactors,andmedicationson
symptoms such as erectile dysfunction. It
is therefore especially important to ade-
quately assess biochemical testosterone
status. This assessment is complicated by
low SHBG levels, which have long been
associatedwithinsulinresistance,leading
to suggestions that low testosterone levels
in type 2 diabetes are due to low SHBG
rather than to reductions in bioactive tes-
tosterone fractions. This suggestion has
been refuted by studies showing low free
and bioavailable testosterone levels in
men with type 2 diabetes (2) and meta-
analysis data suggesting relatively small
changes in SHBG in men with diabetes
(22). The realization that statin treatment
may reduce total testosterone and SHBG
levels in this patient group serves to refo-
cus attention to a subgroup who are par-
ticularly likely to have low SHBG levels
with the potential for a misdiagnosis of
hypogonadism.
In summary, this large data set is the
ﬁrst to suggest a signiﬁcant effect of st-
atins in lowering total testosterone and
SHBG levels in a population of men with
type 2 diabetes. The ﬁndings have impor-
tant implications for the diagnosis of hy-
pogonadism in men receiving statin
treatment. The opportunity to conduct
similar studies of men with type 2 diabe-
tes,comparingmentreatedwithstatinsto
untreated men, has now probably passed
owing to the almost ubiquitous use of
statins in this group. Limitations of this
study are its observational nature and the
resultant inability to prove causality. Sta-
tin-treated men did not differ from other
men in terms of age, blood pressure, obe-
sity, or glycemic control, but unidentiﬁed
confounders cannot be excluded. There-
fore, our ﬁndings require conﬁrmation in
appropriately powered randomized con-
trolled trials. Further longitudinal or in-
terventional studies are also needed to
assess the effects of statins on androgen
statusinvariouspatientgroupsandcould
include assessment of gonadotrophins
and prolactin, which were not measured
here. Researchers should also investigate
mechanismsthatleadtochangesinSHBG
and total testosterone in this context.
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